Alec Saul Eidelman, D.M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Dental, Graduate | 1 | 2017 | 48 | 0.570 |
Why?
|
| School Admission Criteria | 1 | 2017 | 107 | 0.530 |
Why?
|
| Educational Measurement | 1 | 2017 | 1255 | 0.340 |
Why?
|
| Gingivitis | 1 | 2023 | 124 | 0.200 |
Why?
|
| North America | 1 | 2022 | 1276 | 0.160 |
Why?
|
| Education, Dental | 1 | 2021 | 221 | 0.160 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2018 | 350 | 0.130 |
Why?
|
| Phthalazines | 1 | 2018 | 383 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2023 | 942 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2018 | 2223 | 0.120 |
Why?
|
| Chaperonin 60 | 1 | 2013 | 97 | 0.110 |
Why?
|
| Students | 1 | 2022 | 1741 | 0.100 |
Why?
|
| Learning | 1 | 2021 | 1740 | 0.100 |
Why?
|
| HMGB1 Protein | 1 | 2013 | 137 | 0.100 |
Why?
|
| Cystectomy | 1 | 2016 | 634 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 1784 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 2139 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2016 | 1263 | 0.090 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2013 | 587 | 0.080 |
Why?
|
| Curriculum | 1 | 2021 | 3743 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2917 | 0.070 |
Why?
|
| Piperazines | 1 | 2018 | 2523 | 0.070 |
Why?
|
| Survivors | 1 | 2016 | 2371 | 0.060 |
Why?
|
| Hypertension | 1 | 2023 | 8540 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2018 | 10451 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2018 | 2932 | 0.040 |
Why?
|
| Oral Health | 1 | 2023 | 492 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2021 | 54423 | 0.030 |
Why?
|
| New York | 1 | 2019 | 874 | 0.030 |
Why?
|
| Humans | 7 | 2023 | 761596 | 0.030 |
Why?
|
| Urination Disorders | 1 | 2016 | 238 | 0.030 |
Why?
|
| Quality of Life | 1 | 2016 | 13367 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 11122 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 613 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2016 | 357 | 0.030 |
Why?
|
| United States | 2 | 2019 | 72340 | 0.030 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2013 | 125 | 0.020 |
Why?
|
| Intestinal Diseases | 1 | 2016 | 504 | 0.020 |
Why?
|
| Muscles | 1 | 2016 | 1576 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2013 | 347 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 2850 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 605 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 632 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 2898 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2013 | 579 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 16990 | 0.020 |
Why?
|
| Propensity Score | 1 | 2016 | 1913 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2016 | 1824 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3597 | 0.020 |
Why?
|
| Cell Survival | 1 | 2018 | 5791 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3514 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 1410 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2023 | 4687 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6815 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6484 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4576 | 0.020 |
Why?
|
| Public Health | 1 | 2019 | 2669 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 10766 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5035 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 3624 | 0.010 |
Why?
|
| RNA Interference | 1 | 2013 | 2832 | 0.010 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 1943 | 0.010 |
Why?
|
| Research Design | 1 | 2019 | 6180 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12059 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 11120 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5337 | 0.010 |
Why?
|
| Peptides | 1 | 2013 | 4358 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10212 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9490 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8554 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 26129 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 39106 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 39969 | 0.010 |
Why?
|
| Aged | 2 | 2016 | 169310 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 30053 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 58984 | 0.010 |
Why?
|
| Male | 2 | 2016 | 360846 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2016 | 80647 | 0.000 |
Why?
|
| Mice | 1 | 2013 | 81539 | 0.000 |
Why?
|
| Middle Aged | 1 | 2016 | 220921 | 0.000 |
Why?
|
| Animals | 1 | 2013 | 168475 | 0.000 |
Why?
|
| Female | 1 | 2016 | 392705 | 0.000 |
Why?
|